Changes

no edit summary
Line 64: Line 64:     
H3-K27M mutation defines the entity.  K27M mutation occurs in either of 2 genes, H3F3A or HIST1H3B, which encode the histone H3 variants, H3.3 and H3.1, respectively (3).
 
H3-K27M mutation defines the entity.  K27M mutation occurs in either of 2 genes, H3F3A or HIST1H3B, which encode the histone H3 variants, H3.3 and H3.1, respectively (3).
Cooperating genetic alterations include: TP53 and ATRX mutations. A subset of K27M+ DIPGs have ACVR1 missense mutations (encodes the activin A receptor type-1 transmembrane protein, that lead to activation of the BMP-TGF signaling pathway). Other alterations found in K27M+ DIPGs include PIK3CA mutation, PDGFRA mutation or amplification, PPM1D mutation, and amplification of cell cycle genes including CCND1, CDK4 and CDK6 (3).
+
Cooperating genetic alterations include: TP53 and ATRX mutations. A subset of K27M+ DIPGs have ACVR1 missense mutations (encodes the activin A receptor type-1 transmembrane protein, that lead to activation of the BMP-TGF signaling pathway). Other alterations found in K27M+ DIPGs include PIK3CA mutation, PDGFRA mutation or amplification, PPM1D mutation, and amplification of cell cycle genes including CCND1, CDK4 and CDK6 (3).
    
==Genomic Gain/Loss/LOH==
 
==Genomic Gain/Loss/LOH==
Line 97: Line 97:  
===Additional Description:===
 
===Additional Description:===
   −
Mutually exclusive: IDH1 mutation, EGFR amplification
+
'''Mutually exclusive''': IDH1 mutation, EGFR amplification
 
Rare co-occurrence: BRAF V600E
 
Rare co-occurrence: BRAF V600E
    
==Gene Mutations (SNV/INDEL)==
 
==Gene Mutations (SNV/INDEL)==
  −
Put your text here or fill in the table
      
{| class="wikitable sortable"
 
{| class="wikitable sortable"
Line 108: Line 106:  
! Mutation % !! Mutation
 
! Mutation % !! Mutation
 
|-
 
|-
| TP53 || R273H || Tumor Suppressor || LOF || 20%
+
| 100% || H3F3A or HIST1H3B/C K27M mutation – by definition
 +
|-
 +
| ~70% || TP53, PPM1D, CHEK2, ATM
 +
|-
 +
| ~50% || PDGFRA, PIK3CA, PIK3R1, PTEN
 +
|-
 +
| ~20% || ACVR1 (DIPG)
 
|}
 
|}
  −
===Additional Description:===
     −
*Other Mutations
+
{| class="wikitable sortable"
Put your text here
+
|-
*Concomitant Mutations
+
! Other Mutations !! Concomitant Mutations  
Put your text here
+
|-
*Secondary Mutations
+
| || C228T TERT promoter mut
Put your text here
+
|-
*Mutually Exclusive
+
| || activating mutation or fusions targeting FGFR1 (1)
Put your text here
+
|-
 +
| || NTRK fusion ~4% pontine gliomas
 +
|}
    
==Epigenomics (Methylation)==
 
==Epigenomics (Methylation)==
Line 148: Line 152:     
==Links==
 
==Links==
  −
Put your links here
      
==References==
 
==References==
Line 171: Line 173:     
8. Khuong-Quang D-A, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathologica 2012;124:439-447.
 
8. Khuong-Quang D-A, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathologica 2012;124:439-447.
 +
 +
[[Category:Brain, Cancer Genes H, Diseases G]]
275

edits